Michael Lie-A-Ling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael Lie-A-Ling has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Georges Lacaud
Stem Cell Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK
8 shared publications - Roshana Thambyrajah
Departamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain
3 shared publications Jason S. Carroll
Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK
2 shared publications- Muhammad Zaki Hidayatullah Fadlullah
Huntsman Cancer Institute University of Utah Salt Lake City Utah USA
2 shared publications - Renaud Mevel
University Hospital Basel, Switzerland
2 shared publications Robert Sellers
2 shared publications
Latest Publications
- Open Access
A CITE-seq atlas of mouse embryonic hematopoiesis maps endothelial heterogeneity and reveals emerging HSC-associated states
The emergence of hematopoietic stem cells (HSCs) from hemogenic endothelium during embryonic development is a tightly regulated process in which only a restricted population acquires molecular features associated with long-term hematopoietic potential. Although endothelial-to-hematopoietic transition (EHT) has been extensively characterized, the transcriptional and phenotypic heterogeneity accompanying the emergence of HSC-associated states remains incompletely understood. Here, we generated an integrated single-cell transcriptomic and surface-protein atlas of mouse embryonic hematopoiesis using CITE-seq across E9.5, E10.25 and E11.5 aorta-gonad-mesonephros (AGM) regions and E11.5 foetal liver. Analysis of lineage-associated transcriptional programmes distinguished arterial, venous, hemogenic and HSC-associated states, with HSC-associated signatures occupying a more restricted distribution than broader hematopoietic specification programmes. Hlf expression closely corresponded with HSC-associated transcriptional signatures and CD27 surface-protein abundance, identifying a potentially useful immunophenotypic feature for prospective enrichment of HSC-associated populations. Graph-based connectivity, diffusion pseudotime and RNA velocity analyses revealed heterogeneous relationships among endothelial and hemogenic populations, suggesting an inferred progression from arterial preHSC-HE through arterial HSC-HE towards more advanced HSC-associated states. Notably, analysis of E9.5 endothelial cells identified a restricted subset exhibiting elevated RNA velocity-derived connectivity towards arterial preHSC-HE. These cells displayed distinct transcriptional features with enrichment of pathways associated with cell adhesion, junctional organization and signalling. Differences in selected surface proteins further distinguished endothelial cells with high and low predicted connectivity. In parallel, analysis of arterial hemogenic populations revealed changes in transcriptional programmes and surface-protein expression along inferred developmental trajectories, highlighting coordinated molecular and immunophenotypic remodeling during HSC-associated development. Together, these findings provide a multimodal framework for resolving endothelial heterogeneity and identifying candidate cellular states associated with early HSC emergence. By linking transcriptional signatures to measurable surface phenotypes, this atlas offers experimentally testable strategies for investigating the developmental conditions that precede HSC-associated identity, while distinguishing computationally inferred trajectories from functionally established HSC fate.
Open AccessA CITE-seq atlas of mouse embryonic hematopoiesis maps endothelial heterogeneity and reveals emerging HSC-associated states
The emergence of hematopoietic stem cells (HSCs) from hemogenic endothelium during embryonic development is a tightly regulated process in which only a restricted population acquires molecular features associated with long-term hematopoietic potential. Although endothelial-to-hematopoietic transition (EHT) has been extensively characterized, the transcriptional and phenotypic heterogeneity accompanying the emergence of HSC-associated states remains incompletely understood. Here, we generated an integrated single-cell transcriptomic and surface-protein atlas of mouse embryonic hematopoiesis using CITE-seq across E9.5, E10.25 and E11.5 aorta-gonad-mesonephros (AGM) regions and E11.5 foetal liver. Analysis of lineage-associated transcriptional programmes distinguished arterial, venous, hemogenic and HSC-associated states, with HSC-associated signatures occupying a more restricted distribution than broader hematopoietic specification programmes. Hlf expression closely corresponded with HSC-associated transcriptional signatures and CD27 surface-protein abundance, identifying a potentially useful immunophenotypic feature for prospective enrichment of HSC-associated populations. Graph-based connectivity, diffusion pseudotime and RNA velocity analyses revealed heterogeneous relationships among endothelial and hemogenic populations, suggesting an inferred progression from arterial preHSC-HE through arterial HSC-HE towards more advanced HSC-associated states. Notably, analysis of E9.5 endothelial cells identified a restricted subset exhibiting elevated RNA velocity-derived connectivity towards arterial preHSC-HE. These cells displayed distinct transcriptional features with enrichment of pathways associated with cell adhesion, junctional organization and signalling. Differences in selected surface proteins further distinguished endothelial cells with high and low predicted connectivity. In parallel, analysis of arterial hemogenic populations revealed changes in transcriptional programmes and surface-protein expression along inferred developmental trajectories, highlighting coordinated molecular and immunophenotypic remodeling during HSC-associated development. Together, these findings provide a multimodal framework for resolving endothelial heterogeneity and identifying candidate cellular states associated with early HSC emergence. By linking transcriptional signatures to measurable surface phenotypes, this atlas offers experimentally testable strategies for investigating the developmental conditions that precede HSC-associated identity, while distinguishing computationally inferred trajectories from functionally established HSC fate.
- Open Access
Epigenetic silencing of transposable elements by IRF2BP2 is a selective dependency of myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy with limited curative treatment options. Transposable elements (TEs) are now recognized as key regulators of genome function, with aberrant activation implicated in cancer. However, their tumor-type-specific roles remain poorly characterized. Using single-cell Perturb-seq, we systematically screened for chromatin-associated regulators in primary AML patient cells to uncover dependencies required for leukemia cell viability. Our screen identified IRF2BP2 as an AML-selective dependency, functioning as a repressor of TE expression. Loss of IRF2BP2 induced differentiation, apoptosis, and impaired leukemic cell fitness, phenotypes linked to transcriptional activation of TEs, particularly evolutionarily young human endogenous retrovirus K (HERV-K). Mechanistically, IRF2BP2 cooperates with TRIM28 and DNMT1 to epigenetically silence TE expression. CRISPR-mediated activation of HERV-K/LTR5_Hs recapitulated the phenotypic effects of IRF2BP2 loss, while targeted re-silencing of HERV-K/LTR5_Hs partially rescued the effects, establishing a causal link between TE regulation and AML maintenance. Our findings highlight tumor-suppressive functions of TEs in leukemia and reveal IRF2BP2 as a key regulator of TE silencing in AML. Targeting the epigenetic machinery governing TE repression may represent a promising therapeutic avenue for differentiation-inducing and immunomodulatory strategies in AML.
Open AccessEpigenetic silencing of transposable elements by IRF2BP2 is a selective dependency of myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous malignancy with limited curative treatment options. Transposable elements (TEs) are now recognized as key regulators of genome function, with aberrant activation implicated in cancer. However, their tumor-type-specific roles remain poorly characterized. Using single-cell Perturb-seq, we systematically screened for chromatin-associated regulators in primary AML patient cells to uncover dependencies required for leukemia cell viability. Our screen identified IRF2BP2 as an AML-selective dependency, functioning as a repressor of TE expression. Loss of IRF2BP2 induced differentiation, apoptosis, and impaired leukemic cell fitness, phenotypes linked to transcriptional activation of TEs, particularly evolutionarily young human endogenous retrovirus K (HERV-K). Mechanistically, IRF2BP2 cooperates with TRIM28 and DNMT1 to epigenetically silence TE expression. CRISPR-mediated activation of HERV-K/LTR5_Hs recapitulated the phenotypic effects of IRF2BP2 loss, while targeted re-silencing of HERV-K/LTR5_Hs partially rescued the effects, establishing a causal link between TE regulation and AML maintenance. Our findings highlight tumor-suppressive functions of TEs in leukemia and reveal IRF2BP2 as a key regulator of TE silencing in AML. Targeting the epigenetic machinery governing TE repression may represent a promising therapeutic avenue for differentiation-inducing and immunomodulatory strategies in AML.
- Open Access
- 11 November 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (12) , 1642-1661
Single-cell profiling reveals three endothelial-to-hematopoietic transitions with divergent isoform expression landscapes
Hemogenic endothelium (HE) is recognized as the origin of all definitive blood cells, including hematopoietic stem cells (HSCs); however, the mechanisms governing the hematopoietic progenitor versus HSC fate choice within the HE remain unknown. Here we combine differentiation assays with full-length single-cell transcriptome data for extra-embryonic yolk sac (YS) and intra-embryonic aorta–gonad–mesonephros (AGM) region HE populations. We identified and localized three differentiation trajectories, each containing a distinct HE subset: erythromyeloid progenitor-primed HE in the YS plexus, lymphomyeloid progenitor-primed HE in large YS arteries and hematopoietic stem and progenitor cell-primed HE in the AGM. Chromatin modifiers and spliceosome components were enriched in AGM HE. This correlated with a higher isoform complexity of the AGM HE transcriptome. Distinct AGM HE-specific isoform expression patterns were observed for a broad range of genes, including stemness-associated factors like Runx1 . Our data form a unique resource for studying cell fate decisions in different HE populations.
- 11 November 2025
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 4 (12) , 1642-1661
Open AccessSingle-cell profiling reveals three endothelial-to-hematopoietic transitions with divergent isoform expression landscapes
Hemogenic endothelium (HE) is recognized as the origin of all definitive blood cells, including hematopoietic stem cells (HSCs); however, the mechanisms governing the hematopoietic progenitor versus HSC fate choice within the HE remain unknown. Here we combine differentiation assays with full-length single-cell transcriptome data for extra-embryonic yolk sac (YS) and intra-embryonic aorta–gonad–mesonephros (AGM) region HE populations. We identified and localized three differentiation trajectories, each containing a distinct HE subset: erythromyeloid progenitor-primed HE in the YS plexus, lymphomyeloid progenitor-primed HE in large YS arteries and hematopoietic stem and progenitor cell-primed HE in the AGM. Chromatin modifiers and spliceosome components were enriched in AGM HE. This correlated with a higher isoform complexity of the AGM HE transcriptome. Distinct AGM HE-specific isoform expression patterns were observed for a broad range of genes, including stemness-associated factors like Runx1 . Our data form a unique resource for studying cell fate decisions in different HE populations.
- Open Access
- 20 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (3) , 343-356
Murine AGM single-cell profiling identifies a continuum of hemogenic endothelium differentiation marked by ACE
In vitro generation and expansion of hematopoietic stem cells (HSCs) holds great promise for the treatment of any ailment that relies on bone marrow or blood transplantation. To achieve this, it is essential to resolve the molecular and cellular pathways that govern HSC formation in the embryo. HSCs first emerge in the aorta-gonad-mesonephros (AGM) region, where a rare subset of endothelial cells, hemogenic endothelium (HE), undergoes an endothelial-to-hematopoietic transition (EHT). Here, we present full-length single-cell RNA sequencing (scRNA-seq) of the EHT process with a focus on HE and dorsal aorta niche cells. By using Runx1b and Gfi1/1b transgenic reporter mouse models to isolate HE, we uncovered that the pre-HE to HE continuum is specifically marked by angiotensin-I converting enzyme (ACE) expression. We established that HE cells begin to enter the cell cycle near the time of EHT initiation when their morphology still resembles endothelial cells. We further demonstrated that RUNX1 AGM niche cells consist of vascular smooth muscle cells and PDGFRa+ mesenchymal cells and can functionally support hematopoiesis. Overall, our study provides new insights into HE differentiation toward HSC and the role of AGM RUNX1+ niche cells in this process. Our expansive scRNA-seq datasets represents a powerful resource to investigate these processes further.
- 20 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (3) , 343-356
Open AccessMurine AGM single-cell profiling identifies a continuum of hemogenic endothelium differentiation marked by ACE
In vitro generation and expansion of hematopoietic stem cells (HSCs) holds great promise for the treatment of any ailment that relies on bone marrow or blood transplantation. To achieve this, it is essential to resolve the molecular and cellular pathways that govern HSC formation in the embryo. HSCs first emerge in the aorta-gonad-mesonephros (AGM) region, where a rare subset of endothelial cells, hemogenic endothelium (HE), undergoes an endothelial-to-hematopoietic transition (EHT). Here, we present full-length single-cell RNA sequencing (scRNA-seq) of the EHT process with a focus on HE and dorsal aorta niche cells. By using Runx1b and Gfi1/1b transgenic reporter mouse models to isolate HE, we uncovered that the pre-HE to HE continuum is specifically marked by angiotensin-I converting enzyme (ACE) expression. We established that HE cells begin to enter the cell cycle near the time of EHT initiation when their morphology still resembles endothelial cells. We further demonstrated that RUNX1 AGM niche cells consist of vascular smooth muscle cells and PDGFRa+ mesenchymal cells and can functionally support hematopoiesis. Overall, our study provides new insights into HE differentiation toward HSC and the role of AGM RUNX1+ niche cells in this process. Our expansive scRNA-seq datasets represents a powerful resource to investigate these processes further.
- Open Access
- 21 September 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (12) , 109725
Enhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia
- 21 September 2021
- Published by Elsevier in Cell Reports
- Vol. 36 (12) , 109725
Open AccessEnhancer recruitment of transcription repressors RUNX1 and TLE3 by mis-expressed FOXC1 blocks differentiation in acute myeloid leukemia
- Open Access
- 20 March 2021
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-17
Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia
Background: B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most common pediatric cancer. Identifying key players involved in proliferation of BCP-ALL cells is crucial to propose new therapeutic targets. Runt Related Transcription Factor 1 (RUNX1) and Core-Binding Factor Runt Domain Alpha Subunit 2 Translocated To 3 (CBFA2T3, ETO2, MTG16) are master regulators of hematopoiesis and are implicated in leukemia. Methods: We worked with BCP-ALL mononuclear bone marrow patients’ cells and BCP-ALL cell lines, and performed Chromatin Immunoprecipitations followed by Sequencing (ChIP-Seq), co-immunoprecipitations (co-IP), proximity ligation assays (PLA), luciferase reporter assays and mouse xenograft models. Results: We demonstrated that CBFA2T3 transcript levels correlate with RUNX1 expression in the pediatric t(12;21) ETV6-RUNX1 BCP-ALL. By ChIP-Seq in BCP-ALL patients’ cells and cell lines, we found that RUNX1 is recruited on its promoter and on an enhancer of CBFA2T3 located − 2 kb upstream CBFA2T3 promoter and that, subsequently, the transcription factor RUNX1 drives both RUNX1 and CBFA2T3 expression. We demonstrated that, mechanistically, RUNX1 and CBFA2T3 can be part of the same complex allowing CBFA2T3 to strongly potentiate the activity of the transcription factor RUNX1. Finally, we characterized a CBFA2T3-mimicking peptide that inhibits the interaction between RUNX1 and CBFA2T3, abrogating the activity of this transcription complex and reducing BCP-ALL lymphoblast proliferation. Conclusions: Altogether, our findings reveal a novel and important activation loop between the transcription regulator CBFA2T3 and the transcription factor RUNX1 that promotes BCP-ALL proliferation, supporting the development of an innovative therapeutic approach based on the NHR2 subdomain of CBFA2T3 protein.
- 20 March 2021
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 14 (1) , 1-17
Open AccessReduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia
Background: B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most common pediatric cancer. Identifying key players involved in proliferation of BCP-ALL cells is crucial to propose new therapeutic targets. Runt Related Transcription Factor 1 (RUNX1) and Core-Binding Factor Runt Domain Alpha Subunit 2 Translocated To 3 (CBFA2T3, ETO2, MTG16) are master regulators of hematopoiesis and are implicated in leukemia. Methods: We worked with BCP-ALL mononuclear bone marrow patients’ cells and BCP-ALL cell lines, and performed Chromatin Immunoprecipitations followed by Sequencing (ChIP-Seq), co-immunoprecipitations (co-IP), proximity ligation assays (PLA), luciferase reporter assays and mouse xenograft models. Results: We demonstrated that CBFA2T3 transcript levels correlate with RUNX1 expression in the pediatric t(12;21) ETV6-RUNX1 BCP-ALL. By ChIP-Seq in BCP-ALL patients’ cells and cell lines, we found that RUNX1 is recruited on its promoter and on an enhancer of CBFA2T3 located − 2 kb upstream CBFA2T3 promoter and that, subsequently, the transcription factor RUNX1 drives both RUNX1 and CBFA2T3 expression. We demonstrated that, mechanistically, RUNX1 and CBFA2T3 can be part of the same complex allowing CBFA2T3 to strongly potentiate the activity of the transcription factor RUNX1. Finally, we characterized a CBFA2T3-mimicking peptide that inhibits the interaction between RUNX1 and CBFA2T3, abrogating the activity of this transcription complex and reducing BCP-ALL lymphoblast proliferation. Conclusions: Altogether, our findings reveal a novel and important activation loop between the transcription regulator CBFA2T3 and the transcription factor RUNX1 that promotes BCP-ALL proliferation, supporting the development of an innovative therapeutic approach based on the NHR2 subdomain of CBFA2T3 protein.
- Open Access
- 18 February 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Contributions of Embryonic HSC-Independent Hematopoiesis to Organogenesis and the Adult Hematopoietic System
During ontogeny, the establishment of the hematopoietic system takes place in several phases, separated both in time and location. The process is initiated extra-embryonically in the yolk sac (YS) and concludes in the main arteries of the embryo with the formation of hematopoietic stem cells (HSC). Initially, it was thought that HSC-independent hematopoietic YS cells were transient, and only required to bridge the gap to HSC activity. However, in recent years it has become clear that these cells also contribute to embryonic organogenesis, including the emergence of HSCs. Furthermore, some of these early HSC-independent YS cells persist into adulthood as distinct hematopoietic populations. These previously unrecognized abilities of embryonic HSC-independent hematopoietic cells constitute a new field of interest. Here, we aim to provide a succinct overview of the current knowledge regarding the contribution of YS-derived hematopoietic cells to the development of the embryo and the adult hematopoietic system.
- 18 February 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessContributions of Embryonic HSC-Independent Hematopoiesis to Organogenesis and the Adult Hematopoietic System
During ontogeny, the establishment of the hematopoietic system takes place in several phases, separated both in time and location. The process is initiated extra-embryonically in the yolk sac (YS) and concludes in the main arteries of the embryo with the formation of hematopoietic stem cells (HSC). Initially, it was thought that HSC-independent hematopoietic YS cells were transient, and only required to bridge the gap to HSC activity. However, in recent years it has become clear that these cells also contribute to embryonic organogenesis, including the emergence of HSCs. Furthermore, some of these early HSC-independent YS cells persist into adulthood as distinct hematopoietic populations. These previously unrecognized abilities of embryonic HSC-independent hematopoietic cells constitute a new field of interest. Here, we aim to provide a succinct overview of the current knowledge regarding the contribution of YS-derived hematopoietic cells to the development of the embryo and the adult hematopoietic system.
- Open Access
- 15 February 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (3) , e52164
CUL2LRR1, TRAIP and p97 control CMG helicase disassembly in the mammalian cell cycle
The eukaryotic replisome is disassembled in each cell cycle, dependent upon ubiquitylation of the CMG helicase. Studies of Saccharomyces cerevisiae , Caenorhabditis elegans and Xenopus laevis have revealed surprising evolutionary diversity in the ubiquitin ligases that control CMG ubiquitylation, but regulated disassembly of the mammalian replisome has yet to be explored. Here, we describe a model system for studying the ubiquitylation and chromatin extraction of the mammalian CMG replisome, based on mouse embryonic stem cells. We show that the ubiquitin ligase CUL2 LRR1 is required for ubiquitylation of the CMG-MCM7 subunit during S-phase, leading to disassembly by the p97 ATPase. Moreover, a second pathway of CMG disassembly is activated during mitosis, dependent upon the TRAIP ubiquitin ligase that is mutated in primordial dwarfism and mis-regulated in various cancers. These findings indicate that replisome disassembly in diverse metazoa is regulated by a conserved pair of ubiquitin ligases, distinct from those present in other eukaryotes.
- 15 February 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (3) , e52164
Open AccessCUL2LRR1, TRAIP and p97 control CMG helicase disassembly in the mammalian cell cycle
The eukaryotic replisome is disassembled in each cell cycle, dependent upon ubiquitylation of the CMG helicase. Studies of Saccharomyces cerevisiae , Caenorhabditis elegans and Xenopus laevis have revealed surprising evolutionary diversity in the ubiquitin ligases that control CMG ubiquitylation, but regulated disassembly of the mammalian replisome has yet to be explored. Here, we describe a model system for studying the ubiquitylation and chromatin extraction of the mammalian CMG replisome, based on mouse embryonic stem cells. We show that the ubiquitin ligase CUL2 LRR1 is required for ubiquitylation of the CMG-MCM7 subunit during S-phase, leading to disassembly by the p97 ATPase. Moreover, a second pathway of CMG disassembly is activated during mitosis, dependent upon the TRAIP ubiquitin ligase that is mutated in primordial dwarfism and mis-regulated in various cancers. These findings indicate that replisome disassembly in diverse metazoa is regulated by a conserved pair of ubiquitin ligases, distinct from those present in other eukaryotes.
- Open Access
- 1 February 2020
- Published by Korean Society for Molecular and Cellular Biology
- Vol. 43 (2) , 126-138
RUNX1 Dosage in Development and Cancer
The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.
- 1 February 2020
- Published by Korean Society for Molecular and Cellular Biology
- Vol. 43 (2) , 126-138
Open AccessRUNX1 Dosage in Development and Cancer
The transcription factor RUNX1 first came to prominence due to its involvement in the t(8;21) translocation in acute myeloid leukemia (AML). Since this discovery, RUNX1 has been shown to play important roles not only in leukemia but also in the ontogeny of the normal hematopoietic system. Although it is currently still challenging to fully assess the different parameters regulating RUNX1 dosage, it has become clear that the dose of RUNX1 can greatly affect both leukemia and normal hematopoietic development. It is also becoming evident that varying levels of RUNX1 expression can be used as markers of tumor progression not only in the hematopoietic system, but also in non-hematopoietic cancers. Here, we provide an overview of the current knowledge of the effects of RUNX1 dosage in normal development of both hematopoietic and epithelial tissues and their associated cancers.